Ibrance

Phase 2Small molecule

Pfizer

Ibrance is one of 64 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Breast CancerActive, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Megace

Bristol-Myers Squibb

Preclinical

4 2

Zolymbus

AbbVie

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Ibrance

Pfizer

Phase 2

2 5

Acupan

YYonsei University

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Paracetamol

GSK

Preclinical

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Not yet recruiting· Pfizer logo

Pfizer··NCT06962969·1,000 enrolled

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

Completed·HHospital San Carlos, Madrid··NCT04874025·815 enrolled

Metastatic Prostate Cancer1 trial

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02059213·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ibrance. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibrance compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibrance. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Ibrance

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News